Multicenter Study of the Safety and Efficacy of NAFT-500 in Tinea Pedis

A Phase 3 Double-Blind, Randomized, Placebo-Controlled, Multicenter, Parallel Group Evaluation of the Efficacy and Safety of NAFT-500 in Subjects With Tinea Pedis

A research study to compare the safety and effectiveness of an investigational medication called NAFT-500 to placebo, when used in subjects with tinea pedis (athlete's foot).

Study Overview

• Status: Completed
• Conditions: Tinea Pedis; Athlete's Foot
• Intervention / Treatment: Drug: NAFT-500; Drug: Placebo 2-weeks; Drug: Naftin 1%; Drug: Placebo 4-weeks

Detailed Description

To evaluate the efficacy and safety of NAFT-500 compared to placebo in the treatment of subjects with potassium hydroxide (KOH) and culture positive symptomatic tinea pedis.

• Study Type: Interventional
• Enrollment (Actual): 707
• Phase: Phase 3

Contacts and Locations

Study Locations

• United States
  • Alabama
    • Birmingham, Alabama, United States, 35209
      • Radiant Research
  • California
    • Los Angeles, California, United States, 90010-3209
      • Dr. Felix Sigal
    • San Francisco, California, United States, 94115
      • University of California San Francisco, Dept of Dermatology
  • Florida
    • Miami, Florida, United States, 33175
      • FXM Research
    • Miramar, Florida, United States, 33027
      • FXM Research
  • Illinois
    • Buffalo Grove, Illinois, United States, 60089
      • Glazer Dermatology
  • Louisiana
    • New Orleans, Louisiana, United States, 70112
      • Tulane University Health Services
  • Michigan
    • Grand Blanc, Michigan, United States, 48439
      • Silverton Skin Institute
  • North Carolina
    • High Point, North Carolina, United States, 27262
      • Zoe Draelos, MD
  • Ohio
    • Euclid, Ohio, United States, 44118
      • Haber Dermatology
  • Oregon
    • Portland, Oregon, United States, 97210
      • Oregon Dermatology and Research Center
  • Pennsylvania
    • Philadelphia, Pennsylvania, United States, 19103
      • Paddington Testing Company
    • Philadelphia, Pennsylvania, United States, 19107
      • Temple University School of Podiatric Medicine
  • South Carolina
    • Mt. Pleasant, South Carolina, United States, 29464
      • Coastal Carolina Research Center
  • Texas
    • College Station, Texas, United States, 77845
      • J & S Studies
    • Dallas, Texas, United States, 75234
      • Research Across America
    • Plano, Texas, United States, 75093
      • Research Across America

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 12 years and older (Child, Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

1. Review and sign a statement of Informed Consent and HIPAA authorization.
2. For minors (less than 18 years), the parent/legal guardian must complete the informed consent process AND the subject must complete the assent process and sign the appropriate form (if age appropriate).
3. Males or non-pregnant females ≥12 years of age, of any race or sex. Females of childbearing potential must have a negative urine pregnancy test.
4. Presence of tinea pedis on one or both feet characterized by clinical evidence of a tinea infection (at least moderate erythema, moderate scaling, and mild pruritus)based on signs and symptoms.
5. KOH positive and culture positive baseline skin scrapings obtained from the site most severely affected or a representative site of the overall severity.
6. Subjects must be in good health and free from any clinically significant disease that might interfere with the study evaluations.
7. Subject must be able to understand the requirements of the study and willing to comply with the study requirements.

Exclusion Criteria:

1. A life-threatening condition (ex. autoimmune deficiency syndrome, cancer, unstable angina, or myocardial infarction) within the last 6 months.
2. Subjects with abnormal findings - physical or laboratory - that are considered by the investigator to be clinically important and indicative of conditions that might complicate interpretation of study results.
3. Subjects with a known hypersensitivity to study medications or their components.
4. Subjects who have a recent history or who are currently known to abuse alcohol or drugs.
5. Uncontrolled diabetes mellitus.
6. Hemodialysis or chronic ambulatory peritoneal dialysis therapy.
7. Current diagnosis of immunocompromising conditions.
8. Foot psoriasis, corns and/or callus involving any web spaces, atopic or contact dermatitis.
9. Severe dermatophytoses, onychomycosis (on the evaluated foot), mucocutaneous candidiasis, or bacterial skin infection.
10. Extremely severe tinea pedis (incapacitating).
11. Female subject who is pregnant or lactating, who is not using or does not agree to use an acceptable form of contraception during the study, or who intends to become pregnant during the study (females who are surgically sterilized or post menopausal for at least 2 years are not considered to be of childbearing potential).For the purposes of this study, acceptable forms of birth control include: oral contraceptives, contraceptive patches/implants, double barrier methods (e.g., use of condom and spermicide), IUD, and abstinence with second acceptable method should subject become sexually active.

12. Subjects using the following medications:

    • Topical anti-fungal therapy, foot/shoe powders, or topical corticosteroids applied to the feet within 14 days prior to randomization. Topical terbinafine, butenafine,and naftifine within 30 days prior to randomization
    • Oral anti-fungal therapies 3 months (8 months for oral terbinafine) prior to randomization
    • Systemic antibiotic or corticosteroid treatment within 30 days of randomization
    • Any other significant treatments, except hormonal contraception and multivitamin, at the discretion of the investigator that would interfere with study treatment.
    • Investigational drug within 30 days of randomization

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Double

Number of Arms

4

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: 1; Naftin 2% cream applied daily for 2 weeks	Drug: NAFT-500; topical cream 1 application every day up to 4 weeks weeks
Placebo Comparator: 2; Placebo cream applied daily for two weeks	Drug: Placebo 2-weeks; placebo cream 1 application every day for up to 4 weeks
Active Comparator: 3; Active comparator applied daily for 4 weeks	Drug: Naftin 1%; topical allylamine cream applied once a day for up to 4 weeks
Placebo Comparator: 4; placebo cream applied daily for 4 weeks	Drug: Placebo 4-weeks; topical placebo cream applied once a day for up to 4 weeks

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Percentage of Subjects With Complete Cure at Week 6.	The first primary efficacy variable was the percentage of subjects in the NAFT-500 Cream, 2% or 2-week placebo groups with complete cure at Week 6. The second primary efficacy variable was the percentage of subjects in the Naftin 1% Cream or 4-week placebo groups with complete cure at Week 6. Complete cure was defined as negative mycology results from the central laboratory (dermatophyte culture and KOH) and absence of erythema, scaling, and pruritus that were evaluated using a 4 point severity scale.	Week 6

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Percentage of Subjects With Mycological Cure and Percentage of Subjects With Treatment Effectiveness at Week 6	Mycological Cure was defined as negative KOH result and negative dermatophyte culture at Week 6. Treatment Effectiveness was defined as negative KOH, negative culture, and Scaling, Erythema, and Pruritus grades of 0 or 1 at Week 6.	Week 6

Collaborators and Investigators

• Sponsor: Merz North America, Inc.
• Investigators: Principal Investigator: Lawrence Parish, MD, Paddington Testing Company

Publications and helpful links

General Publications

• Parish LC, Parish JL, Routh HB, Fleischer AB Jr, Avakian EV, Plaum S, Hardas B. A randomized, double-blind, vehicle-controlled efficacy and safety study of naftifine 2% cream in the treatment of tinea pedis. J Drugs Dermatol. 2011 Nov;10(11):1282-8.

Study record dates

Study Major Dates

• Study Start: August 1, 2008
• Primary Completion (Actual): August 1, 2009
• Study Completion (Actual): December 1, 2009

Study Registration Dates

• First Submitted: September 8, 2008
• First Submitted That Met QC Criteria: September 9, 2008
• First Posted (Estimate): September 10, 2008

Study Record Updates

• Last Update Posted (Estimate): April 26, 2013
• Last Update Submitted That Met QC Criteria: April 19, 2013
• Last Verified: April 1, 2013

More Information

Terms related to this study

• Keywords: Tinea Pedis; Athlete's foot
• Additional Relevant MeSH Terms: Skin Diseases; Infections; Foot Diseases; Bacterial Infections and Mycoses; Skin Diseases, Infectious; Mycoses; Skin Manifestations; Dermatomycoses; Foot Dermatoses; Pruritus; Tinea; Tinea Pedis
• Other Study ID Numbers: MUS 90200-0736/1

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No